China's deadly drug problem

    The head of China's drug-safety agency is under investigation for alleged corruption. David Cyranoski looks at how the inquiry might affect the country's fast-growing pharmaceutical industry.

    Access options

    Rent or Buy article

    Get time limited or full article access on ReadCube.


    All prices are NET prices.

    Related links

    Related links

    Related links in Nature Research

    Can China bring its own pipeline to the market?

    Chinese biotech hamstrung by production issues

    Poor enforcement could jeopardize China's drug innovation policy

    Handle with care

    Related external links

    State Food and Drug Administration P.R China

    The National Center for Drug Screening

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    China's deadly drug problem. Nature 446, 598–599 (2007).

    Download citation

    Further reading


    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing